S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:STRO

Sutro Biopharma (STRO) Stock Price, News & Analysis

$5.65
+0.72 (+14.60%)
(As of 03/28/2024 ET)
Today's Range
$4.97
$6.13
50-Day Range
$3.27
$5.65
52-Week Range
$2.01
$6.13
Volume
3.14 million shs
Average Volume
1.09 million shs
Market Capitalization
$352.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.71

Sutro Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
142.7% Upside
$13.71 Price Target
Short Interest
Healthy
3.72% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.60mentions of Sutro Biopharma in the last 14 days
Based on 33 Articles This Week
Insider Trading
Selling Shares
$60,925 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.47) to ($2.92) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.69 out of 5 stars

Medical Sector

71st out of 939 stocks

Biological Products, Except Diagnostic Industry

12th out of 158 stocks

STRO stock logo

About Sutro Biopharma Stock (NASDAQ:STRO)

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. Its pre-clinical product candidate STRO-003, a ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

STRO Stock Price History

STRO Stock News Headlines

4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Navigating 4 Analyst Ratings For Sutro Biopharma
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
TD Cowen Sticks to Its Buy Rating for Sutro Biopharma (STRO)
See More Headlines
Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/29/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:STRO
Fax
N/A
Employees
298
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.71
High Stock Price Target
$25.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+142.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-119,200,000.00
Pretax Margin
-57.63%

Debt

Sales & Book Value

Annual Sales
$153.73 million
Book Value
$3.78 per share

Miscellaneous

Free Float
58,134,000
Market Cap
$352.79 million
Optionable
Optionable
Beta
0.95
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. William J. Newell J.D. (Age 66)
    CEO & Director
    Comp: $1.07M
  • Ms. Jane Chung R.Ph. (Age 52)
    President & COO
    Comp: $934.64k
  • Dr. James R. Swartz DSc
    Ph.D., Sc.D., Founder
  • Mr. Edward C. Albini M.B.A (Age 66)
    CFO & Secretary
    Comp: $596.4k
  • Dr. Venkatesh Srinivasan Ph.d.
    Chief Technical Operations Officer
  • Dr. Hans-Peter Gerber Ph.D.
    Chief Scientific Officer
  • Mr. David Pauling J.D.
    M.A., General Counsel
  • Ms. Linda A. Fitzpatrick (Age 67)
    Chief People & Communications Officer
    Comp: $595.79k
  • Dr. Nicki Vasquez Ph.D. (Age 61)
    Chief Portfolio Strategy & Alliance Officer
  • Dr. Anne Elizabeth Borgman-Hagey M.D. (Age 55)
    Chief Medical Officer

STRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Sutro Biopharma stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STRO shares.
View STRO analyst ratings
or view top-rated stocks.

What is Sutro Biopharma's stock price target for 2024?

7 equities research analysts have issued 12-month price objectives for Sutro Biopharma's shares. Their STRO share price targets range from $8.00 to $25.00. On average, they anticipate the company's share price to reach $13.71 in the next twelve months. This suggests a possible upside of 142.7% from the stock's current price.
View analysts price targets for STRO
or view top-rated stocks among Wall Street analysts.

How have STRO shares performed in 2024?

Sutro Biopharma's stock was trading at $4.29 at the beginning of the year. Since then, STRO shares have increased by 31.7% and is now trading at $5.65.
View the best growth stocks for 2024 here
.

When is Sutro Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our STRO earnings forecast
.

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.65) by $0.02. The company had revenue of $8.52 million for the quarter, compared to the consensus estimate of $8.85 million. Sutro Biopharma had a negative trailing twelve-month return on equity of 71.42% and a negative net margin of 69.47%.

What ETF holds Sutro Biopharma's stock?

Simplify Propel Opportunities ETF holds 120,000 shares of STRO stock, representing 0.53% of its portfolio.

What is William J. Newell's approval rating as Sutro Biopharma's CEO?

11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sutro Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV).

When did Sutro Biopharma IPO?

Sutro Biopharma (STRO) raised $75 million in an initial public offering on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Sutro Biopharma's major shareholders?

Sutro Biopharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.74%), Vanguard Group Inc. (4.74%), Franklin Resources Inc. (4.53%), Kynam Capital Management LP (3.28%), Parkman Healthcare Partners LLC (1.97%) and Dimensional Fund Advisors LP (1.87%). Insiders that own company stock include Brunilda Shtylla, Nicki Vasquez and William J Newell.
View institutional ownership trends
.

How do I buy shares of Sutro Biopharma?

Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:STRO) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners